Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 4/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 11/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442003 | 0.78 | XDH (0.46) | XDHGPR84CTSL | |
| SCHEMBL1713153 | 0.72 | CTSL (0.42) | XDHCTSL | |
| SCHEMBL7500956 | 0.69 | XDH (0.46) | XDHGPR84 | |
| SCHEMBL8840458 | 0.67 | XDH (0.39) | XDHGPR84ELANE | |
| SCHEMBL11012125 | 0.66 | TYRO3 (0.38) | XDH | |
| SCHEMBL24846526 | 0.66 | GPR84 (0.50) | XDHGPR84ELANE | |
| SCHEMBL9669758 | 0.65 | XDH (0.50) | XDHGPR84 | |
| SCHEMBL9667342 | 0.64 | XDH (0.49) | XDHGPR84 | |
| SCHEMBL249648 | 0.61 | XDH (0.66) | XDHGPR84 | |
| SCHEMBL7157723 | 0.61 | UPP1 (0.52) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111838-A1 | 6-ARYLAMINO-5-CYANO-4-PYRIMIDINONES AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111838-A1 | 6-ARYLAMINO-5-CYANO-4-PYRIMIDINONES AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-7488733-B2 | 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| US-7488733-B2 | 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| US-7488733-B2 | 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-02-10 | — | — | US | disclosed |
| EP-1905765-A1 | 6-arylamino-5-cyano-4-pyrimidinone as PDE9A-inhibitors | Boehringer Ingelheim International GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1905765-A1 | 6-arylamino-5-cyano-4-pyrimidinone as PDE9A-inhibitors | Boehringer Ingelheim International GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1905765-A1 | 6-arylamino-5-cyano-4-pyrimidinone as PDE9A-inhibitors | Boehringer Ingelheim International GmbH (DE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1644339-B1 | 6-ARYLAMINO-5-CYANO-4-PYRIMIDINONES AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1644339-B1 | 6-ARYLAMINO-5-CYANO-4-PYRIMIDINONES AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2008-01-23 | — | — | EP | disclosed |
| US-20070105881-A1 | 6-Arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors | BAYER HEALTHCARE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105881-A1 | 6-Arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors | BAYER HEALTHCARE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| US-20070105881-A1 | 6-Arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors | BAYER HEALTHCARE AG (DE) | 2007-05-10 | — | — | US | disclosed |
| CN-1835929-A | 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors | BAYER HEALTHCARE AG (DE) | 2006-09-20 | — | — | CN | disclosed |
| CN-1835929-A | 6-arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors | BAYER HEALTHCARE AG (DE) | 2006-09-20 | — | — | CN | disclosed |
| EP-1644339-A1 | 6-ARYLAMINO-5-CYANO-4-PYRIMIDINONES AS PDE9A INHIBITORS | Bayer HealthCare AG (DE) | 2006-04-12 | — | — | EP | disclosed |
| EP-1644339-A1 | 6-ARYLAMINO-5-CYANO-4-PYRIMIDINONES AS PDE9A INHIBITORS | Bayer HealthCare AG (DE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004113306-A1 | 6-ARYLAMINO-5-CYANO-4-PYRIMIDINONES AS PDE9A INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004113306-A1 | 6-ARYLAMINO-5-CYANO-4-PYRIMIDINONES AS PDE9A INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111838-A1 | 6-ARYLAMINO-5-CYANO-4-PYRIMIDINONES AS PDE9A INHIBITORS | PDE9A, PDE2A, PDE5A | XDH 579/4885GPR84 180/4885ELANE 2592/4885 |
| US-20070105881-A1 | 6-Arylamino-5-cyano-4-pyrimidinones as pde9a inhibitors | PDE9A, PDE2A, PDE5A | XDH 579/4885GPR84 180/4885ELANE 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.